These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 14636465

  • 1. [The effect of proton pump inhibitor on intragastric acidity and it relation to S-mephenytoin hydroxylase genetic polymorphism].
    Wang H, Nie YQ, Dai SJ, She QZ, Li YY.
    Zhonghua Nei Ke Za Zhi; 2003 Nov; 42(11):777-80. PubMed ID: 14636465
    [Abstract] [Full Text] [Related]

  • 2. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
    Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, Ishikawa T, Katsube T, Ogawa K, Ohkawa S.
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
    [Abstract] [Full Text] [Related]

  • 3. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects.
    Hu YM, Xu JM, Mei Q, Xu XH, Xu SY.
    Acta Pharmacol Sin; 2005 Mar; 26(3):384-8. PubMed ID: 15715938
    [Abstract] [Full Text] [Related]

  • 4. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
    Adachi K, Katsube T, Kawamura A, Takashima T, Yuki M, Amano K, Ishihara S, Fukuda R, Watanabe M, Kinoshita Y.
    Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
    [Abstract] [Full Text] [Related]

  • 5. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
    Klotz U.
    Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
    [Abstract] [Full Text] [Related]

  • 6. Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans.
    Hu YM, Mei Q, Xu XH, Hu XP, Hu NZ, Xu JM.
    World J Gastroenterol; 2006 Aug 07; 12(29):4750-3. PubMed ID: 16937451
    [Abstract] [Full Text] [Related]

  • 7. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
    Horai Y, Kimura M, Furuie H, Matsuguma K, Irie S, Koga Y, Nagahama T, Murakami M, Matsui T, Yao T, Urae A, Ishizaki T.
    Aliment Pharmacol Ther; 2001 Jun 07; 15(6):793-803. PubMed ID: 11380317
    [Abstract] [Full Text] [Related]

  • 8. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
    Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M, Ohashi K, Ishizaki T.
    Clin Pharmacol Ther; 2004 Oct 07; 76(4):290-301. PubMed ID: 15470328
    [Abstract] [Full Text] [Related]

  • 9. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
    Shimatani T, Inoue M, Kuroiwa T, Xu J, Mieno H, Nakamura M, Tazuma S.
    Clin Pharmacol Ther; 2006 Jan 07; 79(1):144-52. PubMed ID: 16413249
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Rabeprazole experience in Korea; focus on CYP2C19 polymorphism.
    Park SH.
    J Gastroenterol Hepatol; 2005 Dec 07; 20 Suppl():S20-1. PubMed ID: 16359345
    [No Abstract] [Full Text] [Related]

  • 12. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
    Horn J.
    Aliment Pharmacol Ther; 2004 Nov 07; 20 Suppl 6():11-9. PubMed ID: 15496214
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes.
    Sugimoto M, Furuta T, Shirai N, Nakamura A, Kajimura M, Hishida A, Ohashi K, Ishizaki T.
    Clin Pharmacol Ther; 2005 Apr 07; 77(4):302-11. PubMed ID: 15903128
    [Abstract] [Full Text] [Related]

  • 16. A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences.
    Ando T, Kato H, Sugimoto N, Nagao Y, Seto N, Hongo H, Kajikawa H, Isozaki Y, Shimozawa M, Naito Y, Yoshida N, Ishizaki T, Yoshikawa T.
    Dig Dis Sci; 2005 Sep 07; 50(9):1625-31. PubMed ID: 16133961
    [Abstract] [Full Text] [Related]

  • 17. [Comparative effectiveness of the antisecretory action of rabeprazole and esomeprazole in people with rapid metabolism of proton pump inhibitors].
    Morozov SV, Tsodikova OM, Isakov VA, Gushchin AE, Shipulin GA.
    Eksp Klin Gastroenterol; 2003 Sep 07; (6):58-63, 154. PubMed ID: 15065530
    [Abstract] [Full Text] [Related]

  • 18. Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude.
    Luo JY, Niu CY, Wang XQ, Zhu YL, Gong J.
    World J Gastroenterol; 2003 Nov 07; 9(11):2583-6. PubMed ID: 14606102
    [Abstract] [Full Text] [Related]

  • 19. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups.
    Shirai N, Furuta T, Xiao F, Kajimura M, Hanai H, Ohashi K, Ishizaki T.
    Aliment Pharmacol Ther; 2002 Apr 07; 16(4):837-46. PubMed ID: 11929404
    [Abstract] [Full Text] [Related]

  • 20. Effects of different omeprazole dosing on gastric pH in non-variceal upper gastrointestinal bleeding: A randomized prospective study.
    Chwiesko A, Charkiewicz R, Niklinski J, Luczaj W, Skrzydlewska E, Milewski R, Baniukiewicz A, Wroblewski E, Rosolowski M, Dabrowski A.
    J Dig Dis; 2016 Sep 07; 17(9):588-599. PubMed ID: 27518195
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.